Telix Pharmaceuticals Ltd (OTCPK:TLPPF)
$ 10.45 0.15 (1.46%) Market Cap: 3.41 Bil Enterprise Value: 3.34 Bil PE Ratio: 966.88 PB Ratio: 33.63 GF Score: 78/100

Telix Pharmaceuticals Ltd Investor Webinar Transcript

Nov 20, 2023 / 11:15PM GMT
Release Date Price: $6.59
Operator

Thank you for standing by, and welcome to the Telix Pharmaceuticals Limited TLX591 ProstACT Expert Forum. (Operator Instructions) Today's format is a fireside chat hosted by Dr. Colin Hayward, Group Chief Medical Officer at Telix. Please go ahead.

Colin Hayward
Telix Pharmaceuticals Limited - Group Chief Medical Officer

Great. Thank you very much, and welcome to this interesting webinar PSMA Targeting Radiopharmaceuticals, the ProstACT therapy program with first-in-class our rADCs, TLX591 or Lu-rosopatamab tetraxetan. Now look, there's clearly growing interest in radiopharmaceuticals, in GU oncology as a whole, but especially in prostate cancer given recent data in PSMA 4, for example, the ongoing SPLASH study. But we, of course, have ongoing studies in a recent interim report of SELECT -- ProstACT SELECT, and you have seen the news about ProstACT GLOBAL recruiting the first patient in Australia. So that's a very exciting news for us here at Telix.

And this gives us an opportunity to revisit and reeducate the extensive development program to date and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot